{"id":37156,"date":"2025-02-11T19:06:28","date_gmt":"2025-02-11T13:36:28","guid":{"rendered":"https:\/\/www.nextias.com\/ca\/?p=37156"},"modified":"2025-08-14T13:37:38","modified_gmt":"2025-08-14T08:07:38","slug":"india-pharmaceutical-exports-set-for-10x-growth","status":"publish","type":"post","link":"https:\/\/www.nextias.com\/ca\/current-affairs\/11-02-2025\/india-pharmaceutical-exports-set-for-10x-growth","title":{"rendered":"India&#8217;s Pharmaceutical Exports Set for 10x Growth"},"content":{"rendered":"\n<p><strong>Syllabus: GS 3\/Economy&nbsp;<\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>In News<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>India\u2019s Pharmaceutical exports<\/strong> are projected to reach $350 billion by 2047, a 10-15 times increase from current levels.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\">About India&#8217;s Pharmaceutical industry<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>It has gained international recognition as the &#8220;<strong>Pharmacy of the World<\/strong>,&#8221; particularly for its imperative role in supplying vaccines, essential medicines, and medical supplies during the COVID-19 pandemic and beyond.&nbsp;<\/li>\n\n\n\n<li>The sector has showcased its innovative capabilities and established itself as a crucial global pharmaceutical value chain member.&nbsp;<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Current Status in the Global Market:<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India is the<strong> largest supplier of generic drugs<\/strong> globally, accounting for 20% of global sales.<\/li>\n\n\n\n<li>India ranks <strong>third globally in drug <\/strong>and <strong>pharmaceutical production <\/strong>by volume.<\/li>\n\n\n\n<li>India exports to approximately 200 countries and territories.\n<ul class=\"wp-block-list\">\n<li>The top five destinations for these exports are the USA, Belgium, South Africa, the UK, and Brazil.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>India ranks 11th<\/strong> in pharmaceutical export value, despite being a major global supplier of generics.<\/li>\n\n\n\n<li>The total annual turnover of pharmaceuticals in FY24 was \u20b94.17 lakh crore, growing at an average rate of 10.1 per cent in the last five years.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Export Projections<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India\u2019s pharmaceutical exports are expected to grow from $27 billion in 2023 to $65 billion by 2030.<\/li>\n\n\n\n<li>The shift from volume-based to value-driven growth is key to India\u2019s pharmaceutical sector.<\/li>\n\n\n\n<li>Focus areas for growth include <strong>Active<\/strong><strong>Pharmaceutical Ingredients (APIs), biosimilars, and <\/strong><strong>specialty generic<\/strong><strong>s.<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>API Market Growth: <\/strong>India\u2019s API exports are projected to grow from $5 billion to $80-90 billion by 2047.\n<ul class=\"wp-block-list\">\n<li>Global supply chain diversification, particularly due to the U.S. Biosecure Act, presents an opportunity for India to strengthen API production.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Biosimilars Market Growth: <\/strong>Indian biosimilar exports, currently valued at $0.8 billion, are expected to grow fivefold to $4.2 billion by 2030 and $30-35 billion by 2047. Increased R&amp;D, regulatory simplifications, and capacity expansion will support this growth.\n<ul class=\"wp-block-list\">\n<li>Biosimilars are medications that closely <strong>resemble biologic drugs, produced through living systems <\/strong>such as yeast, bacteria, or animal cells, and exhibit comparable structure and function.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Generic Formulations Growth: <\/strong>Generic formulations make up 70% of India\u2019s pharmaceutical exports, valued at $19 billion.\n<ul class=\"wp-block-list\">\n<li>These are projected to grow to $180-190 billion by 2047, with a shift towards higher-margin specialty generics.<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Policy and Strategic Measures<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The Government of India has implemented several initiatives to promote the pharmaceutical sector and boost investment.&nbsp;\n<ul class=\"wp-block-list\">\n<li>In September 2020, the government introduced the<strong> <a href=\"https:\/\/www.nextias.com\/blog\/production-linked-incentive-pli\/\" data-type=\"link\" data-id=\"https:\/\/www.nextias.com\/blog\/production-linked-incentive-pli\/\">Production Linked Incentive (PLI) scheme <\/a><\/strong>for the pharmaceutical sector under the Self-Reliant India initiative, with a financial outlay of worth Rs.15,000 Crore, and the scheme duration is from 2020-2021 to 2028-29.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>Now ,there is a need for targeted policy measures, strengthening the API industry, addressing export barriers, and establishing country-specific export strategies.<\/li>\n\n\n\n<li>India supplies 55-60% of UNICEF\u2019s vaccines but needs to focus more on <strong>high-value markets<\/strong> via clinical trials and manufacturing investments.<\/li>\n\n\n\n<li>Regulatory harmonization, expansion of production-linked incentives (PLI), and R&amp;D incentives will be key enablers.<\/li>\n<\/ul>\n\n\n<div class=\"wp-block-image\">\n<figure class=\"aligncenter size-full is-resized\"><img data-dominant-color=\"d9cecb\" data-has-transparency=\"false\" loading=\"lazy\" decoding=\"async\" width=\"466\" height=\"506\" src=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/02\/union-budget.png\" alt=\"pharmaceutical exports\" class=\"not-transparent wp-image-37157\" style=\"--dominant-color: #d9cecb; width:436px;height:auto\" srcset=\"https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/02\/union-budget.png 466w, https:\/\/wp-images.nextias.com\/cdn-cgi\/image\/format=auto\/ca\/uploads\/2025\/02\/union-budget-276x300.png 276w\" sizes=\"auto, (max-width: 466px) 100vw, 466px\" \/><\/figure>\n<\/div>\n\n\n<h2 class=\"wp-block-heading\"><strong>Challenges&nbsp;<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India is dealing with several challenges, including<strong> tackling intellectual property rights, lack of research and development <\/strong>etc.&nbsp;<\/li>\n\n\n\n<li>Understanding the political, economic, sociocultural, technological, environmental, and legal factors is vital for assessing the opportunities and challenges in the pharmaceutical market in India.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\"><strong>Conclusion and Way Ahead:<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>India is already a global leader in generic drug supply and aims to move up the value chain with specialty generics, biosimilars, and innovative products.\n<ul class=\"wp-block-list\">\n<li>This shift could help India secure a position among the top five nations in export value by 2047.<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li>India has set its goal to be the &#8220;healthcare custodian of the world,&#8221; with a focus on innovation, R&amp;D, and regulatory processes. And collaboration between academia, industry, and government is key to building a globally competitive pharmaceutical sector.<\/li>\n<\/ul>\n\n\n\n<p><strong>Source: BS<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>India\u2019s Pharmaceutical exports are projected to reach $350 billion by 2047, a 10-15 times increase from current levels.<\/p>\n","protected":false},"author":15,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[21],"tags":[],"class_list":["post-37156","post","type-post","status-publish","format-standard","hentry","category-current-affairs"],"acf":[],"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/37156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/users\/15"}],"replies":[{"embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/comments?post=37156"}],"version-history":[{"count":4,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/37156\/revisions"}],"predecessor-version":[{"id":51330,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/posts\/37156\/revisions\/51330"}],"wp:attachment":[{"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/media?parent=37156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/categories?post=37156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.nextias.com\/ca\/wp-json\/wp\/v2\/tags?post=37156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}